PMDD treatments you haven’t heard of (and more info on the ones you have)

The PMDD Treatment Landscape: What Actually Works—and Why

Premenstrual Dysphoric Disorder (PMDD) is not just “bad PMS.” It is a neuroendocrine condition driven by a dysfunctional response to normal hormonal fluctuations—particularly involving serotonin and the neurosteroid allopregnanolone (ALLO). That biology shapes how it must be treated. The current therapeutic landscape reflects this: every effective intervention targets either brain chemistry, ovarian hormone cycling, or both.

First-Line: SSRIs—and Their Hidden Mechanism

Selective serotonin reuptake inhibitors (SSRIs) remain the gold standard. Roughly 60–70% of women experience some relief. Drugs like sertraline, fluoxetine, and paroxetine can be taken continuously, only during the luteal phase, or even just at symptom onset.

But their effectiveness in PMDD is not just about serotonin. SSRIs also increase levels of allopregnanolone (ALLO), a neurosteroid that regulates the brain’s GABA system—the same pathway implicated in PMDD’s mood volatility. This dual action likely explains why SSRIs often work faster in PMDD than in major depression.

Still, they’re not perfect. Side effects—especially sexual dysfunction—are a leading cause of discontinuation.

Hormonal Control: Flattening the Cycle

If PMDD is triggered by cyclical hormonal shifts, one logical strategy is to eliminate those shifts altogether.

Oral contraceptives (OCPs) like Yaz do exactly that. Formulations containing drospirenone and ethinyl estradiol—especially when taken continuously—can significantly improve both mood and daily functioning. By suppressing ovulation, they reduce the hormonal volatility that drives symptoms.

The trade-off: possible side effects like nausea, breakthrough bleeding, and breast tenderness.

Medical Menopause: GnRH Agonists

For severe PMDD, clinicians may go further: shutting down ovarian function entirely using GnRH agonists (e.g. Lupron).

These drugs induce a temporary menopause by suppressing estrogen and progesterone production. They can be highly effective. That said, low estrogen states bring hot flashes, bone loss, and cardiovascular risk, and mood symptoms can sometimes worsen. To eliminate these symptoms and risks, women use Hormone Replacement Therapy (“add-back”), which is steady doses of estradiol and progesterone. I have found HRT incredibly effective.

Permanent Menopause via Surgery

PMDD may be also treated with bilateral salpingo‑oophorectomy—a permanent solution that eliminates hormonal cycling altogether. Note: a hysterectomy unto itself will not solve the problem as it is the ovaries that produce the hormones. Some literature calls for both a hysterectomy and bilateral salpingo oophorectomy. If your doctor wants to do this, ask why removal of all your organs is necessary. It may not be.

Because of its irreversible nature, this option is typically considered only after all other treatments fail. First, it’s important to do a trial run with a GnRH agonist (e.g. Lupron) for at least 2 to 3 months to ensure that menopause works and to get the HRT add-back right.

Meds you probably haven’t heard of: Sepranolone and ulipristal acetate

The most promising new treatments go directly after PMDD’s underlying biology. Importantly, these therapies represent a long overdue shift toward precision targeting of neurosteroid dysfunction, rather than broad hormonal or antidepressant approaches.

Sepranolone (UC1010) is one such therapy. Instead of boosting ALLO like SSRIs, it blocks ALLO’s effects at the GABA-A receptor, addressing the paradoxical response seen in PMDD. Early studies show meaningful symptom reduction with good tolerability.

Similarly, selective progesterone receptor modulators (SPRMs) like ulipristal acetate (UPA, commonly used as an emergency contraceptive) have shown striking results—with 50% of patients achieving full remission according to one study. UPA acts as a progesterone antagonist in progesterone responsive tissues.  In the brain, progesterone receptors are found throughout the amygdala, hippocampus, hypothalamus, thalamus, and frontal cortex, areas involved in mood regulation. 

This mechanism of action is similar to what is observed in women treated with GnRH agonists like Lupron.  However, the big advantage with ulipristal acetate is that, unlike GnRH agonists, UPA does not lead to such a profound reduction in estrogen levels and hypoestrogenism.  In women treated with UPA, levels of estrogen remain stable in the mid-follicular phase range.  

Helpful, but Limited

Several additional treatments can play supporting roles:

• Spironolactone may reduce bloating, irritability, and cravings

• NSAIDs can help physical symptoms, but not mood

• Danazol suppresses ovulation but is limited by androgenic (masculinizing) side effects

The Bottom Line

PMDD treatment is not one-size-fits-all. The most effective therapies map directly onto the disorder’s biology:

• SSRIs → stabilize serotonin and ALLO

• Hormonal therapies → suppress cyclical triggers

• Emerging drugs → target neurosteroid dysfunction directly

The field is moving toward something more precise: treatments tailored to the specific neurobiological mechanisms driving symptoms in each patient. That shift can’t come soon enough.